Abstract Details

Title A pilot trial of Canakinumab (Ilaris), an IL-1? Receptor antagonist, in the treatment of patients with sporadic Inclusion Body Myositis (sIBM)

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P3 - (-)

Poster/Presentation
Number 444

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
MICHAIL KOSMIDIS PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Marinos C. Dalakas, MD, FAAN (Thomas Jefferson University)	Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Grifols, . Dr. Dalakas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Dysimmune Diseases Foundation. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ARGENX. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Therapeutic Advances in Neurology (TAND). Dr. Dalakas has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink.

��ɫ��